协议约定，前沿生物将获得4000万美元首付款及1300万美元近期里程碑付款，后续还可累计获得最高 9.5亿美元的开发、监管及商业化里程碑付款，并享有两款产品全球净销售额的分级特许权使用费。 分工方面，前沿生物负责一款产品在中国的I期临床试验推进，并完成另一款产品的IND支持性研究， 葛兰素史克则主导两款产品之后所有的全球临床开发、监管申报及商业化活动。 2月23日晚，前沿生物发布公告称，公司已与跨国制药巨头葛兰素史克（GSK）签署独家授权许可协 议。根据该协议，葛兰素史克将获得两款小核酸（siRNA）管线产品在全球范围内的独家开发、生产及 商业化权利，其中一款候选药物已进入新药临床试验申请（IND）阶段，另一款为临床前候选药物。 前沿生物表示，合作将改善公司现金流、优化财务结构，为核心管线研发提供资金保障，同时借助葛兰 素史克的全球资源加速管线国际化转化，并为后续推进产品商业化、拓展全球合作奠定坚实基础。 根据公司2025年业绩预告，公司预计实现营业收入1.4亿元-1.45亿元，同比增长8.13%-11.99%，主要来 自抗HIV创新药艾可宁、代理产品缬康韦及获批的远红外治疗贴的销售收入。同期研发费用预计1. ...

Core Viewpoint - Frontier Biotech has disclosed its performance forecast for the fiscal year 2025, expecting revenue growth while still facing net profit losses due to ongoing investments in R&D and operational costs [1] Group 1: Financial Performance - The company anticipates revenue between 140 million to 145 million yuan for 2025, representing a year-on-year increase of 8.13% to 11.99% [1] - The net profit attributable to shareholders, excluding non-recurring gains and losses, is expected to be a loss of approximately 288 million to 323 million yuan, which indicates a reduction in losses by about 4.31 million to 39.31 million yuan compared to the previous year [1] Group 2: Revenue Sources - Revenue is primarily derived from the sales of the anti-HIV innovative drug Aikening® and the recently approved far-infrared therapy patch [1] - The reduction in net profit losses is attributed to increased revenue and decreased operating expenses [1] Group 3: R&D Investments - The company plans to invest approximately 138 million to 145 million yuan in R&D for 2025, reflecting a year-on-year increase of 0.58% to 5.68% [1] - The focus of R&D is on small nucleic acid new drug development and early-stage research of other new drugs [1] Group 4: R&D Pipeline - Frontier Biotech is developing a multi-tiered R&D pipeline, with a focus on antiviral business and small nucleic acid innovative drugs as the core development line, supplemented by high-end generic drugs [1] - The company has submitted an IND application for the single-target small nucleic acid drug FB701, which has been accepted for clinical application approval [2] - The dual-target small nucleic acid drug FB7011 has entered supportive research for new drug clinical trial applications, and the preclinical candidate molecule for FB7023 has been identified [2] - The company has also initiated preclinical research for FB2004, a novel interferon-α2 mutant, in collaboration with Fudan University [2] - The generic drug FB3002 for treating musculoskeletal pain has received acceptance for its market approval application and is currently under review [2]

Core Insights - The company reported a revenue of 103.37 million yuan for the first three quarters of 2025, representing a year-on-year growth of 12.80% [1] - In Q3 2025, the company achieved a revenue of 44.73 million yuan, with a quarter-on-quarter increase of 47.58%, primarily driven by the sales of its innovative HIV drug and the代理产品缬康韦 [1] - The company invested 83.87 million yuan in R&D during the first three quarters, accounting for 81.13% of its revenue [1] R&D Focus - The company is concentrating its R&D efforts on small nucleic acid drugs, while also advancing the development of long-acting anti-HIV drugs and high-end generic drugs [1] - Two small nucleic acid drugs, FB7013 and FB7011, with First-in-Class potential have been developed, with FB7013 completing GMP batch production and non-clinical studies proceeding as planned [1] - FB7011 has completed efficacy studies in a monkey model for IgA nephropathy [1] Product Development and Commercialization - The company is advancing the R&D of FB3002 and other chemical drug hot melt adhesive products, with its subsidiary obtaining a production license for FB3002 [2] - In the pain management sector, the company has initiated commercial production of two specifications of far-infrared therapeutic patches and is expanding its online marketing channels [2] - New institutional investors, including E Fund Medical Healthcare Mixed Securities Investment Fund and E Fund Taihe Growth Stock Pension Product, have entered the company's top ten shareholders list, holding 2.06% and 1.67% of shares respectively [2]